Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF- κB inhibition and the induction of oxidative stress
J Cell Mol Med. 2024 Apr;28(8):e18333. doi: 10.1111/jcmm.18333.ABSTRACTAcute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a...
Source: Molecular Medicine - April 23, 2024 Category: Molecular Biology Authors: Rafaela G A Costa Maiara de S Oliveira Ana Carolina B da C Rodrigues Suellen L R Silva Ingrid R S B Dias Milena B P Soares Ludmila de Faro Valverde Clarissa Araujo Gurgel Rocha Rosane Borges Dias Daniel P Bezerra Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
GSE239350 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq 2]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex ...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research
GSE224815 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex called the stri...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE224813 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT & TAG]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex c...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada
Acute myeloid leukemia (AML) is considered a genetically heterogeneous disease, with different AML subtypes associated with distinct outcomes.1 Internal tandem duplications of the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are present in approximately 25% of patients with AML and are associated with higher rates of relapse and shorter overall survival.2,3 In these patients, allogeneic hematopoietic cell transplantation (alloHCT) represents a potentially curative treatment option.4 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 23, 2024 Category: Hematology Authors: Bhavik J. Pandya, Linda J Burns, Tao Wang, Bin Xie, Maelys Touya, James Spalding, Alana Block, Gaston Kuperman, Christopher Young Source Type: research
Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer
Heat shock protein 90 (HSP90) is overexpressed in numerous cancers, promotes the maturation of numerous oncoproteins and facilitates cancer cell growth. Certain HSP90 inhibitors have entered clinical trials. A... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - April 22, 2024 Category: Nanotechnology Authors: Lejiao Jia, Huatian Yang, Yue Liu, Ying Zhou, Guosheng Li, Qian Zhou, Yan Xu, Zhiping Huang, Feng Ye, Jingjing Ye, Anchang Liu and Chunyan Ji Tags: Research Source Type: research
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes
CONCLUSIONS: Our study suggests that p53 IHC can be used as a rapid tool (within 24 hours) to aid in the detection of residual disease that may complement MRD-FC or NGS in cases in which the flow cytometry immunophenotype is equivocal and/or the bone marrow aspirate is suboptimal.PMID:38643353 | DOI:10.1093/ajcp/aqae034 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - April 21, 2024 Category: Pathology Authors: Nivaz Brar Lauren Lawrence Eula Fung James L Zehnder Peter L Greenberg Gabriel N Mannis Tian Y Zhang Dita Gratzinger Jean Oak Oscar Silva Jason Kurzer Brent Tan Joshua R Menke Sebastian Fernandez-Pol Source Type: research
A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome
CONCLUSIONS: This report provides novel insights into the leukemogenic potential of the KMT2A::CBL rearrangement and the correlation between gene rearrangements and clinical outcomes.PMID:38643442 | PMC:PMC11033236 | DOI:10.1007/s11033-024-09543-0 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - April 21, 2024 Category: Molecular Biology Authors: Jinglei Yu Fengmei Song Mingming Zhang Pingnan Xiao Jingjing Feng Ruimin Hong Yongxian Hu He Huang Guoqing Wei Source Type: research
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes
CONCLUSIONS: Our study suggests that p53 IHC can be used as a rapid tool (within 24 hours) to aid in the detection of residual disease that may complement MRD-FC or NGS in cases in which the flow cytometry immunophenotype is equivocal and/or the bone marrow aspirate is suboptimal.PMID:38643353 | DOI:10.1093/ajcp/aqae034 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - April 21, 2024 Category: Pathology Authors: Nivaz Brar Lauren Lawrence Eula Fung James L Zehnder Peter L Greenberg Gabriel N Mannis Tian Y Zhang Dita Gratzinger Jean Oak Oscar Silva Jason Kurzer Brent Tan Joshua R Menke Sebastian Fernandez-Pol Source Type: research
Interaction of olive oil-based propolis and caffeic acid phenethyl ester with methylprednisolone used in the treatment of human acute myeloid leukemia
CONCLUSIONS: Propolis and its constituents have the potential to serve as effective adjunctive therapies in chemotherapy.PMID:38643306 | DOI:10.1007/s11033-024-09493-7 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - April 20, 2024 Category: Molecular Biology Authors: Hamide Dogan A Ata Ozcimen Sibel Silici Source Type: research
Cancers, Vol. 16, Pages 1580: T-Cell Engagers & mdash;The Structure and Functional Principle and Application in Hematological Malignancies
Cancers, Vol. 16, Pages 1580: T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies
Cancers doi: 10.3390/cancers16081580
Authors:
Paweł Cech
Katarzyna Skórka
Laura Dziki
Krzysztof Giannopoulos
Recent advancements in cancer immunotherapy have made directing the cellular immune response onto cancer cells a promising strategy for the treatment of hematological malignancies. The introduction of monoclonal antibody-based (mAbs) targeted therapy has significantly improved the prognosis for hematological patients. Facing the issues of mAb-based therapies, a ...
Source: Cancers - April 20, 2024 Category: Cancer & Oncology Authors: Pawe ł Cech Katarzyna Sk órka Laura Dziki Krzysztof Giannopoulos Tags: Review Source Type: research
8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia
Leukemia, Published online: 20 April 2024; doi:10.1038/s41375-024-02222-w8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia (Source: Leukemia)
Source: Leukemia - April 20, 2024 Category: Hematology Authors: Jiamin Guo Ralf Buettner Li Du Zhenlong Li Wei Liu Rui Su Zhenhua Chen Yuan Che Yi Zhang Rui Ma Le Xuan Truong Nguyen Roger E. Moore Pathak Khyatiben Min-Hsuan Chen Pirrotte Patrick Xiwei Wu Guido Marcucci Lili Wang David Horne Jianjun Chen Yanzhong Yang Source Type: research
GSE263911 AML1-ETO and CCND2 overexpression ¬ cooperate to drive acute myeloid leukemia initiation and progression
In conclusion, we confirmed that introduction of the CCND2 gene into the AML/ETO pre-leukemia mice can trigger the development of leukemia. We also confirmed that CCND2 overexpression resulted in the upregulation of the mTOR pathway and inhibiting the pathway may be a therapeutic agent for this subtype of leukemia. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 19, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus Source Type: research
Validation of mutated < em > CEBPA < /em > bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2023.284601. Online ahead of print.ABSTRACTNot available.PMID:38634126 | DOI:10.3324/haematol.2023.284601 (Source: Haematologica)
Source: Haematologica - April 18, 2024 Category: Hematology Authors: Esther Prados De la Torre Josefina Serrano David Mart ínez-Cuadrón Laura Torres Claudia Sargas Rosa Ayala Cristina Bilbao-Sieyro Mar ía Carmen Chillón Mar ía José Larráyoz Elena Soria Clara Aparicio-P érez Juan M Bergua Teresa Bernal Cristina Gil Source Type: research
